サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ゲノムバイオマーカーの世界市場（2020年～2027年）
市場調査レポート
商品コード
1123190

ゲノムバイオマーカーの世界市場（2020年～2027年）

Global Genomic Biomarker Market Research and Forecast 2020-2027
出版日: | 発行: Orion Market Research | ページ情報: 英文 120 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
ゲノムバイオマーカーの世界市場（2020年～2027年）
出版日: 2022年07月25日
発行: Orion Market Research
ページ情報: 英文 120 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のゲノムバイオマーカーの市場規模は、予測期間中にCAGRで15%超の成長が予測されています。市場の成長に寄与している要因は、がん、心血管疾患、神経疾患といった慢性疾患の流行などです。また、ゲノムバイオマーカー分野の研究・投資の増加や、薬品開発パイプラインの強化のためのゲノムバイオマーカーサービスの利用も促進要因となっています。

当レポートでは、世界のゲノムバイオマーカー市場について調査分析し、セグメント分析、地域分析、予測、企業プロファイルなどを提供しています。

目次

第1章 レポートサマリー

第2章 市場の概要と考察

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の発展

第4章 市場の決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界のゲノムバイオマーカー市場：適応疾患別
    • 腫瘍
    • 心臓病
    • 神経病
    • その他
  • 世界のゲノムバイオマーカー：エンドユーザー別
    • 病院
    • 診断・研究ラボ

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他のアジア太平洋
  • その他の地域

第7章 企業プロファイル

  • 23andMe
  • Acobiom SAS
  • Agilent Technologies Inc.
  • Almac Group
  • Banyan Biomarkers, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioMerieux S.A.
  • Celgene Corp.
  • Cofactor Genomics, Inc
  • Destina Genomics Ltd
図表

LIST OF TABLES

  • 1. GLOBAL GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 2. GLOBAL GENOMIC BIOMARKER MARKET BY DISEASE INDICATION, 2019-2026 ($ MILLION)
  • 3. GLOBAL GENOMIC BIOMARKER FOR ONCOLOGY MARKET BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL GENOMIC BIOMARKER FOR CARDIOLOGY MARKET BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL GENOMIC BIOMARKER FOR NEUROLOGY MARKET BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL GENOMIC BIOMARKER FOR OTHER DISEASE INDICATION MARKET BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL GENOMIC BIOMARKER MARKET BY END-USER, 2019-2026 ($ MILLION)
  • 8. GLOBAL GENOMIC BIOMARKER AT HOSPITALS MARKET BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL GENOMIC BIOMARKER AT DIAGNOSTIC AND RESEARCH LABORATORIES MARKET BY REGION,2019-2026 ($ MILLION)
  • 10. GLOBAL GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USERS, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. EUROPEAN GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2019-2026 ($ MILLION)
  • 15. EUROPEAN GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USERS, 2019-2026 ($ MILLION)
  • 16. EUROPEAN GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFIC GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USERS, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 20. REST OF THE WORLD GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2019-2026 ($ MILLION)
  • 21. REST OF THE WORLD GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USERS, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL GENOMIC BIOMARKER MARKET SHARE BY DISEASE INDICATION, 2019 VS 2026 (%)
  • 2. GLOBAL GENOMIC BIOMARKER MARKET SHARE BY END-USERS, 2019 VS 2026 (%)
  • 3. GLOBAL GENOMIC BIOMARKER MARKET SHARE BY GEOGRAPHY, 2019 VS 2026, (%)
  • 4. GLOBAL GENOMIC BIOMARKER FOR ONCOLOGY MARKET BY REGION, 2019 VS 2026 (%)
  • 5. GLOBAL GENOMIC BIOMARKER FOR CARDIOLOGY MARKET BY REGION, 2019 VS 2026 (%)
  • 6. GLOBAL GENOMIC BIOMARKER FOR NEUROLOGY MARKET BY REGION, 2019 VS 2026 (%)
  • 7. GLOBAL GENOMIC BIOMARKER FOR OTHER DISEASE INDICATION MARKET BY REGION, 2019 VS 2026 (%)
  • 8. GLOBAL GENOMIC BIOMARKER AT HOSPITALS MARKET BY REGION, 2019 VS 2026 (%)
  • 9. GLOBAL GENOMIC BIOMARKER AT DIAGNOSTIC AND RESEARCH LABORATORIES MARKET BY REGION, 2019 VS 2026 (%)
  • 10. US GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. CANADA MARKET GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. UK GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. GERMANY GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. SPAIN GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. FRANCE GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. ITALY GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 17. REST OF EUROPE GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 18. INDIA GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 19. CHINA GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 20. JAPAN GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 21. REST OF ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
  • 22. REST OF WORLD GENOMIC BIOMARKER MARKET SIZE, 2019-2026 ($ MILLION)
目次
Product Code: OMR2018308

Genomic Biomarker Market by Disease Indication (Oncology, Cardiology, Neurology, Others), By End-Users (Hospitals, Diagnostic and Research Laboratories) - Global Industry Share, Growth, Competitive Analysis and Forecast Period 2020-2027

The global genomics biomarker market is projected to exhibit a CAGR of over 15% during the forecast period. Genomic biomarkers is a field of science that aims for the collective characterization and quantification of genes. Genomics additionally includes the sequencing and analysis of genomes using high-throughput DNA sequencing and bioinformatics for assembling and analyzing the function and structure of entire genomes. Major factors contributing to the growth of the market include the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, neurological disorders, and others. Other driving factors include increasing research and investment in the field of genomic biomarkers and the use of genomic biomarker services for the enhancement of drug development pipelines.

However, some factors are restraining the market growth that includes reimbursement challenges and limited market capabilities in underdeveloped markets. Genomic biomarkers in the development of personalized medicine and rising demand from emerging economies are the factors to create opportunities for the market across the globe.

Segmental Outlook

The global genomic biomarker market is segmented on the basis of disease indication and end-user. By disease indication, the market is segmented into oncology, cardiology, neurology, and others. By end-user, the market is segmented into hospitals and diagnostic and research laboratories.

Global Genomic Biomarker Market Share by Disease Indication, 2019 (%)

Global Genomic Biomarker Market Share by Disease Indication

Among disease indications, oncology contributed a significant share in 2019. The segmental growth is attributed to the high demand for genomic biomarkers in oncology owing to the rise in the prevalence of cancer and an increasing number of research efforts towards genomic biomarkers for cancer detection and understanding therapeutic responses for individual patients.

Regional Outlooks

Geographically, the global genomic biomarker market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. North America contributed a prominent share in the global genomic biomarker market. Factors contributing to the market growth include the presence of well-developed healthcare infrastructure, high healthcare R&D investments, high healthcare expenditure, and others. Europe is another significant market and holds a considerable market share in the global genomic biomarker market.

Market Players Outlook

Some of the key players of the genomic biomarker market include Agilent Technologies, Inc., Illumina, Inc., Myriad Genetics, Inc., Thermo Fischer Scientific, Inc., Genomic Health Inc., Bio-Rad Laboratories Inc., Second Genomic Therapeutics, and Hologic, Inc. In order to survive in the market, these players adopt different marketing strategies such as a merger and acquisitions, product launch, and geographical expansion. For instance, in 2020, Gilead Sciences, Inc. and Second Genome announced their four-year strategic collaboration to identify biomarkers associated with clinical response and to identify new potential targets and drug candidates for the treatment of IBD (inflammatory bowel disease).

The Report Covers

Market value data analysis of 2019 and forecast to 2026.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Genomic biomarker market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Genomic Biomarker Market
  • Recovery Scenario of Global Genomic Biomarker Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Genomic Biomarker Market By Disease Indication
    • 5.1.1. Oncology
    • 5.1.2. Cardiology
    • 5.1.3. Neurology
    • 5.1.4. Others
  • 5.2. Global Genomic Biomarker By End-Users
    • 5.2.1. Hospitals
    • 5.2.2. Diagnostic And Research Laboratories

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. 23andMe
  • 7.2. Acobiom SAS
  • 7.3. Agilent Technologies Inc.
  • 7.4. Almac Group
  • 7.5. Banyan Biomarkers, Inc.
  • 7.6. Bio-Rad Laboratories, Inc.
  • 7.7. BioMerieux S.A.
  • 7.8. Celgene Corp.
  • 7.9. Cofactor Genomics, Inc
  • 7.10. Destina Genomics Ltd * List not exhaustive